The FDA on May 16, 2019 approved FRAGMIN®, to reduce the recurrence of symptomatic Venous ThromboEmbolism (VTE) in pediatric patients 1 month of age and older. FRAGMIN® is a product of Pfizer, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
Other Pages – Top Ad
Advertisement